New  ||| S:0 E:4 ||| JJ
horizons  ||| S:4 E:13 ||| NNS
in  ||| S:13 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
pharmacologic  ||| S:20 E:34 ||| JJ
approach  ||| S:34 E:43 ||| NN
to  ||| S:43 E:46 ||| TO
hyponatremia ||| S:46 E:58 ||| VB
:  ||| S:58 E:60 ||| :
the  ||| S:60 E:64 ||| DT
V2  ||| S:64 E:67 ||| JJ
receptor  ||| S:67 E:76 ||| NN
antagonists  ||| S:76 E:88 ||| VBD
This  ||| S:88 E:93 ||| DT
article  ||| S:93 E:101 ||| NN
provides  ||| S:101 E:110 ||| VBZ
an  ||| S:110 E:113 ||| DT
overview  ||| S:113 E:122 ||| NN
of  ||| S:122 E:125 ||| IN
the  ||| S:125 E:129 ||| DT
developing  ||| S:129 E:140 ||| VBG
niche  ||| S:140 E:146 ||| NN
for  ||| S:146 E:150 ||| IN
vasopressin  ||| S:150 E:162 ||| CD
2  ||| S:162 E:164 ||| CD
receptor  ||| S:164 E:173 ||| NN
antagonists  ||| S:173 E:185 ||| NNS
( ||| S:185 E:186 ||| -LRB-
vaptans ||| S:186 E:193 ||| LS
)  ||| S:193 E:195 ||| -RRB-
in  ||| S:195 E:198 ||| IN
the  ||| S:198 E:202 ||| DT
management  ||| S:202 E:213 ||| NN
of  ||| S:213 E:216 ||| IN
hyponatremia  ||| S:216 E:229 ||| NN
in  ||| S:229 E:232 ||| IN
clinical  ||| S:232 E:241 ||| JJ
practice ||| S:241 E:249 ||| NN
.  ||| S:249 E:251 ||| .
Specific  ||| S:251 E:260 ||| JJ
areas  ||| S:260 E:266 ||| NNS
of  ||| S:266 E:269 ||| IN
focus  ||| S:269 E:275 ||| NN
include  ||| S:275 E:283 ||| VBP
the  ||| S:283 E:287 ||| DT
physiological  ||| S:287 E:301 ||| NN
and  ||| S:301 E:305 ||| CC
clinical  ||| S:305 E:314 ||| JJ
rationale  ||| S:314 E:324 ||| NN
for  ||| S:324 E:328 ||| IN
use  ||| S:328 E:332 ||| NN
of  ||| S:332 E:335 ||| IN
this  ||| S:335 E:340 ||| DT
class  ||| S:340 E:346 ||| NN
of  ||| S:346 E:349 ||| IN
medications  ||| S:349 E:361 ||| NNS
( ||| S:361 E:362 ||| -LRB-
including  ||| S:362 E:372 ||| VBG
advantages  ||| S:372 E:383 ||| NNS
over  ||| S:383 E:388 ||| IN
older  ||| S:388 E:394 ||| JJR
and  ||| S:394 E:398 ||| CC
less  ||| S:398 E:403 ||| RBR
specific  ||| S:403 E:412 ||| JJ
therapeutic  ||| S:412 E:424 ||| JJ
modalities ||| S:424 E:434 ||| NN
) ||| S:434 E:435 ||| -RRB-
,  ||| S:435 E:437 ||| ,
the  ||| S:437 E:441 ||| DT
practical  ||| S:441 E:451 ||| JJ
limitations  ||| S:451 E:463 ||| NNS
to  ||| S:463 E:466 ||| TO
the  ||| S:466 E:470 ||| DT
use  ||| S:470 E:474 ||| NN
of  ||| S:474 E:477 ||| IN
these  ||| S:477 E:483 ||| DT
new  ||| S:483 E:487 ||| JJ
drugs  ||| S:487 E:493 ||| NNS
( ||| S:493 E:494 ||| -LRB-
including  ||| S:494 E:504 ||| VBG
issues  ||| S:504 E:511 ||| NNS
of  ||| S:511 E:514 ||| IN
tolerability ||| S:514 E:526 ||| NN
,  ||| S:526 E:528 ||| ,
toxicity ||| S:528 E:536 ||| NN
,  ||| S:536 E:538 ||| ,
risk ||| S:538 E:542 ||| NN
,  ||| S:542 E:544 ||| ,
and  ||| S:544 E:548 ||| CC
cost ||| S:548 E:552 ||| NN
) ||| S:552 E:553 ||| -RRB-
,  ||| S:553 E:555 ||| ,
and  ||| S:555 E:559 ||| CC
the  ||| S:559 E:563 ||| DT
unanswered  ||| S:563 E:574 ||| JJ
question  ||| S:574 E:583 ||| NN
of  ||| S:583 E:586 ||| IN
the  ||| S:586 E:590 ||| DT
extent  ||| S:590 E:597 ||| NN
to  ||| S:597 E:600 ||| TO
which  ||| S:600 E:606 ||| WDT
correcting  ||| S:606 E:617 ||| VBP
hyponatremia  ||| S:617 E:630 ||| NNS
will  ||| S:630 E:635 ||| MD
improve  ||| S:635 E:643 ||| VB
clinical  ||| S:643 E:652 ||| JJ
outcomes ||| S:652 E:660 ||| NNS
.  ||| S:660 E:662 ||| .
